← Search & browse all drugs
CARDIOVASCULAR SYSTEM › LIPID MODIFYING AGENTS › LIPID MODIFYING AGENTS, COMBINATIONS › Lipid modifying agents in combination with other drugs
simvastatin, acetylsalicylic acid and ramipril
C10BX04
Forms & Strengths
- Fixed-dose combination capsule: Simvastatin / Acetylsalicylic Acid / Ramipril (various strengths, e.g., 20mg/81mg/5mg, 20mg/81mg/10mg, 40mg/81mg/10mg)
Adult Dosing
- Secondary prevention of cardiovascular events: One capsule daily, individualized based on component titration and tolerability.
- Switching from individual components: Patients stabilized on individual agents of equivalent doses may be switched to the fixed-dose combination.
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established; not recommended for use in children.
Indications
- Secondary prevention of cardiovascular events (myocardial infarction, stroke, and cardiovascular death) in patients with established cardiovascular disease or appropriate risk profiles.
Mechanism of Action
- Simvastatin: Inhibits HMG-CoA reductase, decreasing hepatic cholesterol synthesis and upregulating LDL receptors.
- Acetylsalicylic Acid (ASA): Irreversibly inhibits cyclooxygenase-1 (COX-1), blocking thromboxane A2 synthesis and platelet aggregation.
- Ramipril: Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II and reducing degradation of bradykinin.
Contraindications
- Hypersensitivity to simvastatin, ASA, ramipril, other ACE inhibitors, or any component of the formulation.
- Active liver disease or unexplained persistent elevations of serum transaminases.
- History of angioedema related to previous ACE inhibitor therapy.
- Concomitant use with aliskiren in patients with diabetes mellitus.
- Asthma, rhinitis, or nasal polyps precipitated by salicylates or NSAIDs (due to ASA component).
- Active peptic ulcer disease or bleeding disorders.
- Pregnancy and lactation.
Adverse Reactions
- Simvastatin: Myalgia, myopathy, arthralgia, nasopharyngitis, elevated liver transaminases.
- Acetylsalicylic Acid: Dyspepsia, nausea, abdominal pain, increased bleeding risk, gastrointestinal ulceration.
- Ramipril: Dry persistent cough, hypotension, hyperkalemia, dizziness, headache, angioedema, renal impairment.
Drug Interactions
- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): Significantly increase simvastatin exposure and risk of myopathy/rhabdomyolysis.
- Potassium-sparing diuretics, potassium supplements, or ARBs: Increase risk of severe hyperkalemia with ramipril.
- Anticoagulants (e.g., warfarin, DOACs) or NSAIDs: Increase risk of bleeding when combined with ASA.
- Lithium: Ramipril may reduce lithium elimination, increasing toxicity risk.
Curated Content: Needs Vetting Before Put to Clinical Use